Ovarian Cancer Summit 2022
This page is for UK healthcare professionals only. If you are not a UK healthcare professional, please click here.
MSD in the UK

Ovarian Cancer Summit 2022

About Agenda Speakers
Wednesday, October 12th (9:00 -13:00)

Ovarian Cancer Summit 2022

Personalise Her Treatment

This is a promotional meeting organised and fully funded by AstraZeneca and MSD for UK Healthcare Professionals only. AstraZeneca and MSD products will be discussed at the meeting. Prescribing Information and adverse event reporting will be available at the meeting.

Registrations are now closed.

Prescribing Information and adverse event reporting for Great Britain may be found here and for Northern Ireland here. These links will take you to pages hosted by AstraZeneca.

Meeting Objectives:

  • Provide an educational forum to discuss the latest developments in the treatment and management of ovarian cancer, focussing on real world clinical experience with Lynparza (olaparib) and best practice sharing

  • Gain an understanding of the clinical rationale for Lynparza + bevacizumab combination therapy as well as the mechanisms behind co-targeting tumours

  • Reflect on Lynparza’s long-term efficacy and safety, understanding the clinical importance of maintenance therapy for eligible patients with advanced ovarian cancer

  • Maintain HRD testing numbers and ensure best practice sharing; as well as providing an update on the latest transition plans from Myriad Genetics Inc. to the NHS

For optimal webcast experience, please access via desktop computer/laptop and use the following browsers: Chrome, Edge, Firefox or Safari. Internet Explorer is no longer supported.

Please register below
Ovarian Cancer Summit 2022
Days
Hours
Minutes

Agenda

09:00: Welcome to the Ovarian Cancer Summit 2022: Personalise Her Treatment

Prof. Jonathan Ledermann
 

09:05: Lynparza in the First-line: Key data updates

Prof. Jonathan Ledermann

  • Briefly re-examine of the core data sets from Lynparza’s pivotal first-line trails
  • Review the SOLO-1 7 year survival data, as well as the significance of this in the ovarian cancer treatment space
  • Discuss the rationale for Lynparza monotherapy and Lynparza + bevacizumab, summarising effective methods used to differentiate treatment options for patient groups

 

09:25: Co-targeting in Practice: Lynparza + bevacizumab in advanced ovarian cancer

Prof. Gordon Jayson & Dr Laura Tookman

  • Provide the mechanistic rationale behind Lynparza + bevacizumab maintenance treatment; considering the co-targeting nature of the combination and the benefits this may provide for patients
  • Review the patient experience when using Lynparza + bevacizumab, discussing:
    • The types of patients that benefit most from treatment
    • Effective methods for patient management

10:00: Effectively Using Bevacizumab in Clinic: Workshop session

Dr Laura Tookman
(Workshop facilitated by extended faculty)  

11:10: Break

11:25: Patient Expectations and Motivations: Driving support in first-line advanced ovarian cancer

Ms. Victoria Clare (Ovacome)

  • Analyse the patient motivations and challenges through the treatment pathway, gaining insight on the key stages in which support can be integrated into the patient journey
  • Review effective strategies to discuss treatment options with patients; ensuring they understand the relevance of maintenance therapy in the context of biomarkers as well as the considerations associated with each treatment option
 

11:45: Reflections from the NCRAS Report: Interactive panel session

Prof. Sudha Sundar (+ Panel Q&A session)

  • Presentation: A review of the findings from the NCRAS report, discussing key statistics and the subsequent relevance to clinical practice
  • Panel Q&A session: An interactive session integrating audience interaction in order to gauge opinions on the shared data, to subsequently be followed by discussions/opinions from the panellists
 

12:15: Testing Best Practice: Optimising sample quality and reducing failure rates

Dr Will Loughborough

  • A discussion on the importance of high sample quality and effective sample handling and how this impacts the full MDT; as well as considerations for reducing testing failure rates
 

12:35: Genomics in 2022 and Beyond: Looking to the future of testing

Dr Helene Schlecht

  • An overview of key genomics and pathology programmes ongoing within the NHS; as well as upcoming initiatives which will impact the ovarian cancer testing landscape
  • A summary of the key next steps to transition to ’in-house’ testing, as well as how this will be integrated into the clinical pathway

12:55: Summary and Learnings from the Ovarian Cancer Summit 2022

Prof. Ledermann

13:00: Meeting End - Lunch

Speakers

Prof. Jonathan Ledermann

Prof. Jonathan Ledermann (Meeting Chair)

Professor of Medical Oncology and Clinical Director, UCL Cancer Institute

See more

Prof. Gordon Jayson

Professor of Medical Oncology, University of Manchester



See more
Dr Laura Tookman

Dr Laura Tookman

Consultant Medical Oncologist, Imperial College Healthcare, London

See more
Ovacome Ovarian Cancer

Ms. Victoria Clare

CEO, Ovacome



See more
Prof. Sudha Sundar

Prof. Sudha Sundar

Consultant Clinical Oncologist, City Hospital, Birmingham

See more
Dr.Will Loughborough

Dr Will Loughborough

Consultant Radiologist, Royal United Hospitals

See more

Dr Helene Schlecht

Principle Clinical Scientist, Manchester Centre for Genomic Medicine

See more

Register for the following event now

* This information is required

GB-36968 | Date of preparation: July 2022

To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com
Privacy Policy | Terms of Use
Ovarian Cancer Summit 2022

Merck Sharp & Dohme (UK) Limited.
Registered Office: 120 Moorgate, London EC2M 6UR, United Kingdom.
Registered in England No 233687
Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000). By clicking the above link you will be taken to the MHRA website (a third party website)*

* MSD makes no warranties or representations of any kind as to the accuracy, completeness; reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third-party link does not imply an endorsement or recommendation by MSD.

Welcome to MSD online events

MSD online events are for UK Healthcare Professionals only. They may contain promotional information about MSD pharmaceutical products and therapy areas.

Are you a UK Healthcare Professional registering for an MSD online event?

Yes, I am a Healthcare Professional No, I am not a Healthcare Professional

Prof. Jonathan Ledermann

Prof. Jonathan Ledermann (Meeting Chair)

Professor of Medical Oncology and Clinical Director, UCL Cancer Institute, UK

Prof. Jonathan Ledermann, BSc MD, FRCP FMedSci, is a Professor of Medical Oncology and Clinical Director at UCL Cancer Institute, University College London, and a Consultant Medical Oncologist at UCL Hospitals, London, UK where he has worked for more than 30 years. 

He specialises in the treatment of gynaecological cancers and has led several national and international trials in ovarian cancer. Until recently he was the Director of the Cancer Research UK & UCL Cancer Trials Centre, a large national Academic Cancer Trials Unit which he led for more than 22 years.

He is a Senior Investigator for the National Institute of Health Research (NIHR) and a Fellow of the Academy of Medical Sciences and Editor for ESMO (European Society of Medical Oncology) Gynaecological Cancer Clinical Practice Guidelines.

He is the past Vice President of ESGO and has formerly held roles of the chair of the NCRI UK Gynaecological Cancer Trials, Group, Council member of the BGCS and IGCS. He was also the past chair of the Rare Tumour Group of the Gynaecological Cancer Intergroup.

He serves on Editorial Boards of several scientific journals and has published widely in the areas of clinical trials in gynaecological cancers, experimental therapeutics, guidelines, and education in gynaecological malignancies.

Prof. Gordon Jayson

Professor of Medical Oncology, University of Manchester

Prof. Gordon Jayson qualified in Medicine at the University of Oxford. His subsequent medical and oncology training took place in Manchester and the Christie Hospital. Following a PhD in heparan sulfate biology, he has conducted post-doctoral research that aims to translate the new data from heparan sulfate biology into the clinic. His current programme of work, described above, is directed at the laboratory development of novel oligosaccharides as anti-angiogenic agents and the early and late clinical trial evaluation of this class of drugs. The latter programme aims to identify serological and imaging based biomarkers that will identify the patients who are most likely to benefit from this these agents and which will be used to underpin the development of combination regimens of biological agents. This work is largely focused on ovarian cancer, the disease that Professor Jayson looks after in Christie Hospital.

Dr Laura Tookman

Dr Laura Tookman

Consultant Medical Oncologist, Imperial College Healthcare, London

Dr Laura Tookman is a Consultant Medical Oncologist specialising in gynae-oncology at Imperial College NHS Trust.
Dr Tookman completed her undergraduate training at the University of Cambridge and clinical training at University College London Medical School. She trained in medical oncology at St Bartholomew’s and University College Hospitals London. Her PhD research, at Barts Cancer Institute, investigated a novel treatment for ovarian cancer and was funded by the Medical Research Council. Dr Tookman is involved in a number of clinical trials and has a particular interest in projects aimed at developing the service for patients with gynaecological malignancies. 

Ovacome Ovarian Cancer

Ms. Victoria Clare

CEO, Ovacome

Ovacome is the national UK ovarian cancer charity focused on providing support and information to anyone affected by ovarian cancer. This includes people who have either been diagnosed with the disease or think that they might be at risk, as well as their friends, family and healthcare professionals. They are a strong community of many thousands of people, all working together with the aim of reducing isolation, sharing information, promoting knowledge and supporting anyone affected by ovarian cancer. They have over 4,000 members and each year we support around 18,000 people.

Prof. Sudha Sundar

Prof. Sudha Sundar

Consultant Clinical Oncologist, City Hospital, Birmingham

Prof. Sudha Sundar trained in Obstetrics and Gynaecology at Oxford, and in Gynaecological Oncology at the Three Counties cancer centre, Gloucestershire. Prof. Sundar trained in Molecular Oncology as a Cancer Research UK Clinical Fellow at the Weatherall Institute of Molecular Medicine, Oxford.

Sudha Sundar is a Professor of Gynaecological Cancer at the University of Birmingham and Consultant Gynaecological Oncologist at Pan Birmingham gynaecological cancer care at City Hospital, Birmingham. Sudha leads the Cancer Pillar for Birmingham Health Partners. She has recently completed her term as President of the British Gynaecological Cancer Society as the first female Gynaecological Oncologist to be elected to this post. During her tenure, the BGCS has established Quality performance indicators for ovarian cancer, new initiatives to promote research in gynaecological cancer and doubled membership.

Dr.Will Loughborough

Dr Will Loughborough

Consultant Radiologist, Royal United Hospitals, Bath UK

Dr.Will Loughborough is a Consultant Radiologist at the Royal United Hospitals Bath, sub-specialising in oncological imaging. He is actively involved with the gastrointestinal, gynaecological and urological MDTs. In his role as oncology imaging lead, he has established the whole body MRI imaging service for breast cancer patients in addition to creating bespoke CT imaging protocols for all tumour types and indications. He is the local radiology oncology trials lead, reviewing all new medical oncology trials and assessing whether the radiological capacity and personnel available can meet the requirements of each trial. His main research interest is the radiological assessment of response to systemic oncological therapies using novel imaging techniques.

Recently, he has been working alongside AstraZeneca (AZ) in regards to optimising tumour yield in histological samples for adequate BRCA/HRD analysis in ovarian malignancy. He is currently orchestrating the collection of regional data of histological sampling in this setting, including analysis of imaging and biopsy techniques. Following data analysis, the aim is to collaborate with AZ and professional societies to improve the success of molecular testing in ovarian malignancy and potentially expand to other tumour sites.

Dr Helene Schlecht

Principle Clinical Scientist, Manchester Centre for Genomic Medicine

Following studying for a BSc in Biochemistry at University of Bristol, Dr Helene Schlecht completed a PhD at the University of Sheffield in 2004. In 2004 she started her career as a Clinical Scientist in the genetic diagnostic laboratory at St Mary’s Hospital, Manchester working across rare disease and cancer for a number of years. Helene is currently a Consultant Clinical Scientist, leading the cancer team at the Manchester Genomic Diagnostic Laboratory and is the NW GLH solid tumour scientific lead.